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Abstract
Dominant Vc2Vd2 T-cell subset exist only in primates, and recognize phosphoantigen from selected pathogens including M.
tuberculosis(Mtb). In vivo function of Vc2Vd2 T cells in tuberculosis remains unknown. We conducted mechanistic studies to
determine whether earlier expansion/differentiation of Vc2Vd2 T cells during Mtb infection could increase immune
resistance to tuberculosis in macaques. Phosphoantigen/IL-2 administration specifically induced major expansion and
pulmonary trafficking/accumulation of phosphoantigen-specific Vc2Vd2 T cells, significantly reduced Mtb burdens and
attenuated tuberculosis lesions in lung tissues compared to saline/BSA or IL-2 controls. Expanded Vc2Vd2 T cells
differentiated into multifunctional effector subpopulations capable of producing anti-TB cytokines IFNc, perforin and
granulysin, and co-producing perforin/granulysin in lung tissue. Mechanistically, perforin/granulysin-producing Vc2Vd2 T
cells limited intracellular Mtb growth, and macaque granulysin had Mtb-bactericidal effect, and inhibited intracellular Mtb in
presence of perforin. Furthermore, phosphoantigen/IL2-expanded Vc2Vd2 T effector cells produced IL-12, and their
expansion/differentiation led to enhanced pulmonary responses of peptide-specific CD4+/CD8+ Th1-like cells. These results
provide first in vivo evidence implicating that early expansion/differentiation of Vc2Vd2 T effector cells during Mtb infection
increases resistance to tuberculosis. Thus, data support a rationale for conducting further studies of the cd T-cell-targeted
treatment of established TB, which might ultimately help explore single or adjunctive phosphoantigen expansion of Vc2Vd2
T-cell subset as intervention of MDR-tuberculosis or HIV-related tuberculosis.
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Introduction
Tuberculosis(TB) remains one of the leading causes of morbidity
and mortality worldwide among infectious diseases, and has
become increasingly prevalent and deadly as a result of the
emergence of multi-drug resistant (MDR) TB and HIV/AIDS
pandemic [1,2]. Given the possibility that TB patients usually have
immune dysfunction, immune intervention regulating or enhanc-
ing anti-TB immune responses may be beneficial for clinical
treatment of TB or MDR-TB. Although immune therapy or
adjunctive immune plus antibiotics treatment has been long
considered attractive for clinical treatment of TB, especially MDR
TB, successful treatment modalities have not been identified due
to the lack of an immune regimen that specifically targets immune
components of anti-TB immunity. In fact, little is known about
how human immune cells control a primary Mtb infection, despite
that it is generally believed that human CD4+ T cells are
important for resistance to TB [3,4]. In-depth studies of Mtb-
specific T effector cells may facilitate our understanding of anti-TB
immune mechanisms and help identify potential immune inter-
vention for drug-resistant TB.
Vc2Vd2 T cells exist only in primates, constitute 65–90% of
total human circulating cd T cells, and regulate or contribute to
both innate and adaptive-like immune responses in infections
[5,6,7,8,9]. Vc2Vd2 T cells recognize phosphoantigen (E)-4-
hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP) produced
by M. tuberculosis (Mtb) or other selected pathogens in TCR-
dependent fashion [10,11,12,13]. Our decades-long studies in
non-human primate models contribute to illustrating biology and
immune responses of human Vc2Vd2 T cells in Mtb and other
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infections [6]. Recently, we and others have developed a unique
manipulating system to remarkably expand Vc2Vd2 T cells in vivo.
We showed that administration of phosphoantigen compound plus
IL-2 induced remarkable expansion of Vc2Vd2 T cells, antago-
nized cytokine-induced Foxp3+ Treg, reversed Treg-mediated
immune suppression, and attenuated pneumonic plague lesions in
non-human primates [14,15,16,17]. These findings provide a
rationale for conducting a proof-of-concept study to determine
whether phosphoantigen/IL-2 administration can expand/differ-
entiate Vc2Vd2 T cells, improve immune system and resist TB in
non-human primates. Finding may shed light on cd T-cell-
targeted immune intervention potential using a clinical drug
zoledronate capable of expanding Vc2Vd2 T cells, as this drug is
being tested as cd T-cell-based therapeutic regimen for treatment
of metastatic cancers [18,19]. Studies of Vc2Vd2 T cell-targeted
intervention can only be done in primates, as there is no evidence
that cd T cells from mice and other animals can recognize
phosphoantigen and other microbial antigens [6].
Results
Picostim/IL-2 administration during pulmonary Mtb
infection induced remarkable expansion of Vc2Vd2 T
cells and pulmonary trafficking/accumulation of these
cells
To conduct the proof-of-concept study, macaques were treated
intermittently with the Picostim (identical to HMBPP except one
carbon difference) plus IL-2 regimen [15] at day 23 and day 15,
respectively, after pulmonary Mtb infection. Picostim/IL-2
administration during Mtb infection of macaques reproducibly
induced remarkable expansion of Vc2Vd2 T cells (Fig. 1A). To
minimize variation in evaluating infection/immunity in out-bred
macaques, we performed 3 serial repeated experiments and, in
each in vivo experiment, the test group and 2 control groups were
simultaneously investigated. Vc2Vd2 T cells were expanded up to
60% from base-line 1% of total CD3+ T cells or increased to
absolute mean numbers from,40/ul to,2000/ul after Picostim/
IL-2 administration (Fig. 1A). Notably, expanded Vc2Vd2 T cells
were able to traffic to and accumulate in the pulmonary
compartment during Picostim/IL-2 treatment and Mtb infection
(Fig. 1B). Virtually, such pulmonary accumulation of phosphoan-
tigen-activated Vc2Vd2 T cells was consistent with increases in
these cd T cells in lung interstitial tissues and pulmonary lymphoid
follicles[[14], and data not shown]. In contrast, control IL-2 alone
or saline/BSA treatment did not induce significant increases in
numbers of Vc2Vd2 T cells in the circulation and pulmonary
compartments (Fig. 1a,b). The repeated Picostim/IL-2 treatment
at day 15 after Mtb infection led to a subtle increase in the mean
number of blood Vc2Vd2 T cells compared to the level at day 9,
the time in which numbers of Vc2Vd2 T cells remained higher
than baseline despite declining from the peak expansion following
the initial treatment(Fig. 1a,1b). Thus, these results demonstrated
that Picostim/IL-2 treatment during pulmonary Mtb infection of
macaques induced major expansion of Vc2Vd2 T cells and
pulmonary trafficking/accumulation of these cells.
Picostim/IL2 administration, while expanding Vc2Vd2 T
cells, could lead to reduction in Mtb bacterial burdens
Since Picostim/IL2 regimen induced major expansion and
pulmonary trafficking/accumulation of Vc2Vd2 T cells, we
examined whether this immune intervention could lead to changes
in bacterial burdens after pulmonary Mtb infection. We measured
bacterial CFU counts in lung tissue homogenates from right
caudal lung lobe(infection site), right middle lobe and left caudal
lobe at the end point after Mtb infection. The Picostim/IL2-
treated group exhibited lower numbers of bacilli organisms in lung
tissue homogenates from all studied lung lobes than the saline/
BSA-treated and IL2-treated control groups, particularly in right
middle and left caudal lung lobes than IL-2-treated control group
(Fig. 1c). These findings showed that Picostim/IL-2 administration
in early Mtb infection could expand Vc2Vd2 T cells and lead to
reduction in Mtb bacterial burdens in lungs.
Picostim/IL2 expansion of Vc2Vd2 T cells conferred
immune resistance to TB lesions after pulmonary Mtb
infection
We then sought to determine whether Picostim/IL2 manipu-
lation of Vc2Vd2 T cells would increase resistance to TB lesions in
lungs after Mtb infection. We conducted complete necropsy and
gross pathology studies at day 65 after Mtb infection to examine
detectable resistance to TB pathology and lesions in the Picostim/
IL2-treated group in comparisons with the control groups.
Interestingly, Picostim/IL2-treated macaques exhibited an in-
creased resistance to TB lesions in lungs compared to saline/BSA
and IL2-treated controls. Virtually, four animals (IDs:8022, 8014,
8013, 8006) in Picostim/IL2-treated group did not show any gross
TB lesions in lung tissues (Fig. 2, Fig. S1 in Text S1), three animals
displayed localized TB lesions limited to the right caudal lobe
(infection site) of lungs (Fig. 2), and only two macaques showed
apparent TB lesions involving the right caudal and middle lung
lobes or left lower lobe (Fig. 2, Fig. S1 in Text S1). In contrast, all
control macaques treated with saline/BSA exhibited severe/
extensive caseating and miliary TB lesions or caseation pneumo-
nia, and displayed extensive coalescing granulomas in right
caudal/middle lobes and left lower lobe (Fig. 2, Fig. S1 in Text
S1). TB lesions in these saline/BSA-treated macaques were readily
disseminated to the opposite lung, hilar lymph nodes, and pleural
or extrathoracic organs. All macaques except one in the IL2-
treated control group developed TB lesions, and the lesions were
Author Summary
Tuberculosis(TB), caused by Mycobacterium tuberculo-
sis(Mtb), remains a leading cause of morbidity and
mortality worldwide. While CD4+/CD8+ T cells are protec-
tive, role of cd T cells in TB and other infections remains
unknown in humans. Vc2Vd2 T cells exist only in primates,
represent a dominant circulating cd T-cell subpopulation,
and recognize phosphoantigen from Mtb and some
selected pathogens. Here, we determined whether earlier
expansion/differentiation of Vc2Vd2 T cells during Mtb
infection increased resistance to TB in macaques. Phos-
phoantigen plus IL-2 administration induced expansion
and pulmonary accumulation of Vc2Vd2 T cells, signifi-
cantly reduced Mtb counts and attenuated TB lesions in
lung tissues. Expanded Vc2Vd2 T cells produced anti-TB
cytokines IFNc, perforin and granulysin, and co-produced
perforin and granulysin in lung tissue. Perforin/granulysin-
co-producing Vc2Vd2 T cells limited intracellular Mtb
growth, and macaque granulysin killed Mtb bacteria, and
inhibited intracellular Mtb in presence of perforin.
Furthermore, expansion of Vc2Vd2 T effectors enhanced
pulmonary responses of peptide-specific CD4+/CD8+ T
cells, which correlated with the ability of Vc2Vd2 T effector
cells to produce IL-12. These results provide first evidence
implicating a protective role of Vc2Vd2 T effector cells in
TB, supporting a rationale to explore Vc2Vd2 T-cell-
targeted treatment of drug-resistant TB or HIV-related TB.
Role of Vc2Vd2 T Cells in Immunity to Tuberculosis
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more apparent than those in the Picostim/IL2-treated
group(Fig. 2, Fig. S1 in Text S1). When the gross TB pathology
or lesions was evaluated in details and compared between groups
using the scoring system as we and others previously described
[20,21,22], we found that the Picostim/IL2-treated group
exhibited significantly milder TB lesions or pathology than
saline/BSA-treated and IL2-treated control groups(Fig. 3a). Of
note, the immune resistance to TB lesions after Picostim/IL2
treatment did not appear to be mediated by IL2 since Picostim/
IL2-treated macaques showed less severe TB lesions or pathology
than the IL2 alone group did (Fig. 3a). IL2 alone conferred
detectable resistance to TB lesions compared to BSA/saline, but
could not effectively reduce Mtb bacterial burdens([22], and
Fig. 1c, Fig. 3a), whereas Picostim/IL2 expansion of Vc2Vd2 T
effector cells decreased levels of Mtb infection(Fig. 1c).
Consistently, histopathology analyses also implicated immune
resistance to TB in Picostim/IL2-treated macaques. TB granulo-
mas in all saline/BSA-treated control macaques were apparently
extensive, coalescing and widely necrotic in tissue sections from all
studied lung lobes(Fig. 3b, Fig. S2 in Text S1). TB granulomas
Figure 1. Intermittent Picostim/IL-2 administration during early pulmonary Mtb infection induced major expansion of Vc2Vd2 T
cells and accumulation of them in pulmonary compartment, and led to reduction in Mtb bacterial burdens in lungs. (a)
Representative flow histograms of percentages of Vc2Vd2 T cells gated on CD3(left) at day 1 postinfection (day 4 after 1st treatment) and graph data
(right) of absolute numbers of Vc2Vd2 T cells over time after treatments, respectively, in the blood. Percentages of Vc2Vd2 T cells in CD3 T cells are
indicated in right upper quadruples. Graph data are means with SEM from nine macaques/per group. Vertical arrows denote the times for treatment.
**p,0.01, *p,0.05, by both parametric and nonparametric analyses. (b) BAL fluid (BALF) data in a similar fashion as (a), except that flow data are on
day 8 post infection(day 11 after treatments) and that numbers in graphs (right) are percentages of Vc2Vd2 T cells(n = 9 for each group). Increases in
Vc2Vd2 T cells in BALF consist with accumulation of them in lung tissues of phosphoantigen/IL-2-treated macaques ([14] and data not shown). The
data suggest changes in Vc2Vd2 T cells in the airway of the pulmonary compartment, not precisely in lung tissues. Please see Fig. S3c in Text S1 for
immunohistocheminstry in situ analysis of cd T cells in lung parenchyma and granulomatous tissues). (c) Mean CFU counts of bacilli in lung tissue
homogenates of different lung lobes collected at the end point (at day 65) from Picostim/IL-2-treated and control groups. Lung tissue homogenates
generated from each lobe was serially diluted and used for CFU enumeration(CFU/ml homogenates). **p,0.01, *p,0.05, respectively, by parametric
and nonparametric comparisons between Picostim/IL-2-treated and control groups(n = 9/group). Data from control groups [22] were shown here
again to prove the concept that phosphoantigen/IL2 expansion of Vc2Vd2 T cells can more apparently limit Mtb growth compared to saline/BSA and
IL2 alone controls as all groups were evaluated simultaneously.
doi:10.1371/journal.ppat.1003501.g001
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were seen in lung tissue sections from all IL2-treated macaques
although these animals were less necrotic than saline/BSA-treated
group (Fig. 3b, Fig. S2 in Text S1). Interestingly, among those four
Picostim/IL2-treated macaques that did not show any gross lung
TB lesions at necropsy, three macaques(IDs:8022, 8014,8013) did
not exhibit any detectable microscopic TB granulomas in the lung
tissue sections derived from right caudal and other lung lobes
despite that we employed digital microscopic scanning for extensive
analyses (Fig. 3b, Fig. S2 in Text S1). One of (ID:8006) those four
animals showed only a few tiny, lymphocytic, non-necrotic
microscopic granulomas(Fig. 3b). In other five Picostim/IL2-treated
macaques, microscopic TB granulomas were smaller, more focal
and much less necrotic than those in the saline/BSA-treated
macaques, and similarly non-necrotic or more lymphocytic
compared to IL2-treated macaques (Fig. 3b, Fig. S2 in Text S1).
Taken together, the gross pathology and histopathology results
suggested that Picostim/IL2 expansion of Vc2Vd2 T cells could
confer immune resistance to TB after pulmonary Mtb infection.
Phosphoantigen/IL2-expanded Vc2Vd2 T cells
differentiated to multi-functional effector
subpopulations capable of producing anti-TB cytokines
IFNc, perforin and granulysin, and co-producing perforin/
granulysin in lung tissues
We then undertook mechanistic studies to examine if the
immune resistance to TB coincided with anti-TB effector function
of Vc2Vd2 T cells after Picostim/IL2 administration. Since mouse
IFNc and perforin are needed for anti-TB immunity [23,24,25,26]
and human granulysin kills Mtb [4], we examined if these anti-TB
cytokines could be produced by Picostim-expanded Vc2Vd2 T
cells in the pulmonary compartment. We employed both the
conventional intracellular cytokine staining(ICS) upon in vitro
antigen stimulation and the modified direct ICS assay without in
vitro antigen stimulation since the direct ICS assay had been
demonstrated to be useful for measuring T effector cells that were
close to the in vivo setting during infections [22,27,28,29,30]. We
Figure 2. Picostim/IL2 treatment, while expanding Vc2Vd2 T cells, could confer immune resistance to TB lesions in lungs after
pulmonary Mtb infection. Shown are digital photos of cut sections of lung lobes from 12 representatives of 27 macaques (9 for each group).
Lungs and other organs were obtained in complete necropsy at day 65 after Mtb infection. Macaque ID numbers are shown in upper left corners,
with the right caudal(RC) lobe (infection site) indicated in each photo. Extent and severity of the lesions could be adjudged based on the examples
pointed by large arrows for caseation pneumonia or extensive coalescing granulomas and by small arrows for less coalescing or small granulomas.
Yellow arrows indicate the enlarged hilar lymph nodes with caseation. Note that four Picostim/IL-2–treated macaques (ID 8022, 8014, 8013, 8006: first
two animals shown in this figure and last two shown in Fig. S1 in Text S1) did not show any detectable gross TB lesions. Other five Picostim/IL-2–
treated macaques displayed more focal, less coalescing or less caseating TB granulomas than control groups. (see Fig. S1 in Text S1). Vertical/
horizontal bars at upper right corner of each photo represent the 1-cm scale derived from the fluorescence rulers of original photos. .50% of saline/
BSA and 10% of IL-2–treated controls had extrathoracic TB dissemination, which was not seen in Picostim/IL-2-treated macaques. The efficacy
evaluation was done sequentially in three separate trials each involving Picostim/IL-2 group and control groups of a total of 27 macaques.
doi:10.1371/journal.ppat.1003501.g002
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Figure 3. Picostim/IL2-treated group showed immune resistance to TB lesions in lungs compared to control groups. (a). Graph data of
mean gross pathology scores for Picostim/IL-2-treated and control groups. The scores were calculated and compared as we previously described
[21,43]. n = 9/group. Control groups [22] were included here to prove the concept that phosphoantigen/IL2 expansion of Vc2Vd2 T cells can lead to
increased resistance to TB. (b). Representative histopathology photos for Picostim/IL-2-treated and control groups. Also see Fig. S2 in Text S1 in the
supplementary materials for histopathology from other macaques of three groups. Overall, saline/BSA-treated control macaques (represented in
upper panel) exhibited widespread necrosis, fulminant TB pneumonia, and TB hemorrhage/thrombosis lesions. The alveolar septa are destroyed or
indistinct. Most TB granulomas from IL2-treated macaques tended to be a lack of widespread necrosis, TB pneumonia, or TB hemorrhage in the
sections from the right caudal lung lobe (infection site) and other lobes. In the Picostim/IL-2-treated group (lower panel), three macaques (ID:
8022,8014,8013) exhibited no detectable TB granulomas, four macaques predominantly showed well-contained TB granulomas with lymphocyte cuff,
without widespread necrosis. Two of them exhibited histology similar to what were seen in IL-2-treated macaques. Original magnification6100 for all
photos. See Fig. S2 in Text S1 for similar contrasting data in other controls and IL-2–treated macaques.
doi:10.1371/journal.ppat.1003501.g003
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found that appreciable numbers of Vc2Vd2 T cells in the
pulmonary compartment were able to re-recognize HMBPP
phosphoantigen and produce IFNc over time after the Picostim/
IL-2 administration(Fig. 4a). In fact, Picostim/IL2-expanded
Vc2Vd2 T cells could produce IFNc constitutively without the
need for in vitro HMBPP phosphoantigen stimulation(Fig. S3a in
Text S1). Similarly, pulmonary Vc2Vd2 T effector cells were able to
produce perforin in the presence or absence of HMBPP stimulation,
and these effectors peaked at ,1 week in BAL cells after Mtb
infection (Fig. 4a, Fig. S3a in Text S1). Furthermore, in-situ confocal
imaging studies showed that Vc2Vd2 T effector cells producing
perforin or granulysin were detectable in lung tissue sections derived
from the Picostim/IL2-treated macaques (Fig. 4b, Fig. S3b in Text
S1). Virtually, some of activated Vc2Vd2 T cells in lung tissues from
Picostim/IL2-treated macaques were able to co-produce perforin
and granulysin in situ (Fig. 4b, Fig. S3b in Text S1). In contrast,
saline/BSA- or IL-2-treted control macaques did not show any
perforin/granulysin-co-producing Vc2Vd2 T cells in lung tissues
although perforin-producing cells (non-Vc2) were detectable in IL-
2-treated macaques(Fig. 4b). Immunohistochemistry analysis also
demonstrated that Picostim/IL2-treated macaques exhibited more
Vc2 T cells in lung parenchyma and granulomas tissues than
control IL2-treated and saline/BSA-treated animals even at the end
time point(Fig. S3c in Text S1).
Vc2Vd2 T effector cells producing granulysin/perform
limited intracellular Mtb replication; macaque granulysin/
perforin could inhibit Mtb growth
Given that Picostim-differentiated Vc2Vd2 T cells produced
anti-Mtb cytokines, we presumed that expanded Vc2Vd2 T
effector cells could limit Mtb replication during Mtb infection. To
test this hypothesis, we used the effector T cell-cloning technique
as we previously described [31] to generate phosphoantigen-
activated Vc2Vd2 T effector cells from PBL of Mtb-infected
macaques [21] and assessed them for the ability to regulate
intracellular Mtb replication. These Vc2Vd2 T effector cells
expressed granulysin and perforin, and could limit Mtb growth in
Mtb-infected monocytes (Fig. 5a). Consistently, some Vc2Vd2 T
cells that expanded and differentiated in vivo at 14 days after
Picostim/IL-2 treatment could recognize Mtb-infected autologous
macrophages leading to inhibition of intracellular Mtb growth,
and such inhibition could be reduced by antibodies against
granulysin/perforin(FigS. 3d). The result indicated the need of
granulysin and perforin secretion for anti-Mtb effector function
and confirmed what was described in the in vitro study of human cd
T effector cells [32].
To examine a molecular mechanism whereby Picostim/IL2-
expanded Vc2Vd2 T effector cells inhibited Mtb replication, we
sought to determine whether macaque granulysin or perforin
produced by Picostim-expanded Vc2Vd2 T effector cells exerted
anti-Mtb activities. To this end, granulysin(Gnl) and active domain
of perforin(PC) were expressed and purified using the E. coli
expression system (Fig. S4 in Text S1, [33]), and then evaluated for
the ability to affect extracellular and intracellular Mtb replication.
We designed and produced active component of perforin [34],
because the whole protein of macaque perforin was not optimally
expressed and secreted in the E. coli expression system(data not
shown). The active macaque granulysin killed extracellular Mtb at
a concentration of 50 uM (Fig. 5b, left), and inhibited intracellular
Mtb in monocytes/macrophages in the presence of active PC
(Fig. 5b, right). The Fig. 5b data derived from the new system
producing macaque granulysin/perforin help to explain anti-Mtb
effector function of Vc2Vd2 T cells while confirming the result
from the earlier study of human granulysin [35].
Taken together, these results consisted with the resistance to TB
in Picostim/IL2-treated macaques, supporting the view that
Vc2Vd2 T effector cells could limit intracellular Mtb replication
during Mtb infection via production of granulysin and perforin.
Picostim/IL2-expanded Vc2Vd2 T cells constitutively
produced IL-12, and expansion of Vc2Vd2 T cells led to
enhanced pulmonary immune responses of Mtb peptide-
specific ab CD4+ and CD8+ T effector cells
Recent in vitro studies have shown that activated human
Vc2Vd2 T cells can function as APC presenting peptide antigens
to ab T cells [36]. However, whether Vc2Vd2 T effector cells can
enhance anti-microbial responses in vivo remains poorly charac-
terized. As an additional mechanistic study, we investigated
whether in vivo expansion of Vc2Vd2 T cells after Picostim/IL-2
treatment could augment immune responses of peptide Ag-specific
ab T cells in the context of immune resistance to Mtb infection.
To this end, we compared frequencies of mycobacterium-specific
CD4+ and CD8+ T effector cells producing anti-TB cytokine
IFNc between Picostim/IL2-treated and control groups of
macaques since phosphoantigen was highly specific for Vc2Vd2
T cells, but not for CD4+ or CD8+ T cells. Picostim/IL2
expansion of Vc2Vd2 T cells did not lead to significant increases
in frequencies of PPD-specific IFNc-producing ab T effector cells
in the blood when compared to those from IL-2-treated group(-
data not shown). However, Picostim/IL2-treated macaques
exhibited significantly greater numbers of Mtb-specific IFNc-
producing CD4+ T effector cells in the pulmonary compartment
than control macaques treated with IL2 alone or saline/BSA
during early phase of Mtb infection(Fig. 6a). Picostim/IL2
immune intervention also promoted greater increases in pulmo-
nary PPD-specific IFNc-producing CD8+ T effector cells than IL2
alone and saline control treatment(Fig. 6a). Moreover, an
increased ability of CD4+/CD8+ T cells to constitutively produce
Figure 4. Phosphoantigen-expanded Vc2Vd2 T cells in pulmonary compartments differentiated and produced anti-Mtb cytokines
IFNc, perforin and granulysin, and co-produced perforin/granulysin in lung tissues. (a). Representative flow cytometry histograms of IFNc-
producing (upper panels) and perforin-producing Vc2Vd2 T effector cells gated on CD3 at day 8 postinfection and graph data (right) of numbers of
Vc2Vd2 T effector cells in BALF collected overtime from Picostim/IL-2-treated and control groups. Effector cells were measured by ICS after HMBPP
stimulation. n = 9/group for IFNc effectors; n = 7/group for perforin effectors. * and ** denote p,0.05 and p,0.01, respectively, when analyzed by
ANOVA or student t test. Effector cells measured by direct ICS without HMBPP stimulation was shown in Fig. S3a in Text S1. (b) Representative in situ
confocal microscopic images (636NA) of Vc2Vd2 T effector cells producing perforin and granulysin in lung tissue sections. The bottom two panels
show that Vc2 TCR (green) appear to co-localize with perforin (purple) and granulysin (red) in the merge images(co-localization marked by arrows) in
lung tissue sections, suggesting that Vc2 cells co-produce perforin and granulysin. Images at the top and middle panels show that no Vc2 or
granulysin was detectable in the lung tissue sections from representative macaques treated with saline or IL-2 alone, although perforin was detected
in sections from IL-2-treated macaques. 10 um bars are indicated in images. All tissues sections were prepared from right middle and caudal lung
lobes. Vc2 cells were temporarily interpreted as Vc2Vd2 T cells as our previous studies demonstrated that Picostim or HMBPP/IL-2 exclusively
expanded Vc2Vd2 T cells in vivo and most cd T cells in lungs during Mtb infection were Vc2Vd2 T cells. Control isotype IgG did not give rise to any
immune staining in the lung TB tissue sections (data not shown). See Sup Fig. 3b for additional confocal microscopic images of other macaques.
doi:10.1371/journal.ppat.1003501.g004
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IFNc in the setting relevant to the in vivo condition was also seen in
Picostim/IL2-treated macaques, as we detected an increased
number of pulmonary CD4+ and CD8+ T effector cells capable of
producing IFNc without the need for peptide Ag stimulation in
vitro (Fig. S5 in Text S1). We certainly realized that the pulmonary
mobilization of these effector cells could not directly prove one of
the immune mechanisms whereby expanded cd T cells contribute
to anti-TB immunity.
Since CD4+/CD8+ Th1 immune responses were often initiated
and promoted by IL-12 production, we examined if Picostim-
expanded Vc2Vd2 T effector cells were able to produce IL-12
leading to the enhanced pulmonary Th1 responses in Picostim/IL-
2-treated macaques. Interestingly, we detected significant numbers
of Vc2Vd2 T effector cells capable of constitutively producing IL-12
without the need for in vitro HMBPP stimulation after Picostim/IL2
administration, but not saline/BSA or IL2 alone treatment (Fig. 6b).
These results suggested that Picostim/IL2-expanded Vc2Vd2 T
cells were able to constitutively produce IL-12, and their expansion/
differentiation led to enhanced pulmonary immune responses of
Mtb peptide-specific ab CD4+/CD8+ T effector cells.
Discussion
Despite that human cd T cells have been discovered for more
than 25 years, the role of Mtb-specific Vc2Vd2 T cells in immunity
against TB and other infectious diseases has not been defined in
humans. Data from the current proof-of-concept study suggest that
Picostim/IL-2 immune intervention during pulmonary Mtb infec-
tion can expand/differentiate Vc2Vd2 T effector cells, limit Mtb
replication/dissemination, and attenuate TB lesions in non-human
primates. Earlier negative finding for cd T cells in mouse TB model
does not appear to be conclusive [26], as there is no evidence that
mouse cd T cells can recognize Mtb phosphoantigen or other
antigens [6]. Nowwe present the first in vivo evidence suggesting that
phosphoantigen/IL2 expansion of Vc2Vd2 T cells can induce
immune resistance to severe TB. This finding extends in vitro data
demonstrating anti-Mtb effector function of human cd T cells
[8,37,38,39], and appears to be novel and relevant to elucidating in
vivo function of human Vc2Vd2 T cells.
Picostim/IL2 expansion/differentiation of Vc2Vd2 T effector
cells mimics the natural immune stimulation driven by Mtb
Figure 5. Vc2Vd2 T effector cells and macaque granulysin/perforin restricted Mtb growth. (a). Shown on left are real time quantitative
PCR data for mRNA expression levels of perforin and granulysin expressed by macaque Vc2Vd2 T effector cells capable of restricting intracellular Mtb
growth. The quantitation was done using the methods as we previously described [40]. Data are means with SEM from phosphoantigen-activated
Vc2Vd2 T effector cells from 3 Mtb-infected macaques in 2 independent experiments. Control B cells were purified using CD20 mAb and
immunemagnetic beads [29]. Right panel shows that co-culturing of Mtb-infected monocytes with Vc2Vd2 T effector cells expressing perforin/
granulysin led to reduction in CFU bacterial counts. (b). Graph curves show that recombinant granulysin(Gnl), but not perforin(PC), killed extracellular
Mtb (left); Gnl+PC inhibited intracellular Mtb growth(right). Data are the killing or inhibiting percentage of extracellular or intracellular Mtb CFUs
relative to Mtb CFUs in medium-only control(see Methods). Data are means derived from Mtb-infected monocytes from three macaques in 3
experiments. ** p,0.001; ***p,0.0001; ****p,0.00001, by student t test.
doi:10.1371/journal.ppat.1003501.g005
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Figure 6. Picostim/IL2 expansion of Vc2Vd2 T cells led to enhanced pulmonary immune responses of Mtb peptide-specific ab CD4+/
CD8+ T effector cells, and Picostim/IL2-expanded Vc2Vd2 T cells in vivo could produce IL-12 constitutive without the need for in vitro
Role of Vc2Vd2 T Cells in Immunity to Tuberculosis
PLOS Pathogens | www.plospathogens.org 9 August 2013 | Volume 9 | Issue 8 | e1003501
phosphoantigen and IL2 in Mtb infection. The Picostim/IL2
intervention simply moves the selective expansion/differentiation
of Vc2Vd2 T effector cells earlier and to a greater extent, since
production of phospohoantigen and IL2 will become prominent
only in a later phase of Mtb infection. In fact, Mtb infection or
BCG vaccination can induce remarkable expansion of Vc2Vd2 T
cells at ,3–4 weeks postinfection, and rapid recall expansion of
Vc2Vd2 T cells in BCG-vaccinated macaques correlates with the
vaccine-induced protection against life-threatening TB [9]. Earlier
and greater-magnitude expansion of Vc2Vd2 T cells during Mtb
infection appears to create a proof-of-concept setting in which to
examine immune function of Mtb-specific Vc2Vd2 T effector cells
in primates, as rapid clonal expansion and pulmonary trafficking
of Mtb-specific CD4+/CD8+ T cells have been interpreted as
important immune events in immunity against TB in macaques
[40]. The resistance to TB after phosphoantigen treatment could
be due to killing and blunting of Mtb as they enter the pulmonary
compartment after infection, since the treatment is given during
early Mtb infection rather than established TB disease.
It should be pointed out that only some of expanded Vc2Vd2 T
cell subpopulations are protective although almost all cd T cells
expressing Vc2Vd2 TCR have been shown to recognize Mtb
phosphoantigen [6,10,39]. Consistent with this concept, we and
others including Spencer/Hoft et al have repeatedly shown that
only certain percentages of expanded Vc2Vd2 T cells can
differentiate into effector cells capable of producing anti-TB
cytokines or inhibiting mycobacterial growth during phosphoanti-
gen/IL2 treatment or Mtb infection. It is also noteworthy that
phosphoantigen/IL2 treatment of chronic TB may not be as
efficacious as the treatment of early-phase or primary TB, since
patients with chronic TB often exhibits anergy or insufficiency of cd
T cell effector function [6]. In addition, an in vitro study by Spencer/
Hoft et al showed that large numbers of phosphoantigen-activated
cd T cells could not recognize BCG-infected target cells [39].
The immune resistance to Mtb infection and TB appears to
result from multi-effector functions of phosphoantigen-expanded
Vc2Vd2 T cells rather than IL-2 immune activation since
Picostim/IL2-treated macaques exhibited lower Mtb CFU counts
and milder TB lesions in most lung lobes than IL2-treated
controls. It is noteworthy that IL-2 treatment confers resistance to
TB lesions compared to BSA/saline treatment [22]. Notably, IL-2
administration predominantly expanded CD4+CD25+Foxp3+
Treg [15], whereas Picostim/IL-2 regimen massively expanded
Vc2Vd2 T cells in mycobacterial infection, down-regulated IL2-
induced expansion of IL2-induced Treg cells and reversed Treg-
associated immune suppression in vivo [15]. Although IL2 alone is
protective against TB lesions, the regimen could not effectively
reduce Mtb bacterial burdens([22], Fig. 1c, Fig. 3a). Picostim/IL2
expansion of Vc2Vd2 T cells led to a decreased level of Mtb
infection and more apparent resistance to TB than IL-2 expansion
of Treg and T effectors([22], Fig. 1c, Fig. 3a). Of note, all IL2-
treated macaques except one developed TB lesions. In contrast,
approximately 45% of phosphoantigen/IL2-treated macaques did
not exhibit detectable TB, and gross pathology scores in
phosphoantigen/IL2-treated group are significantly smaller than
those in IL2-treated and saline/BSA-treated control groups. While
anti-Mtb effector function of phosphoantigen-expanded Vc2Vd2
T cells appears to be relevant to controlling Mtb infection and
attenuating TB, the ability of Vc2Vd2 T effectors to mediate
homeostasis against inflammation and tissue damage may also
contribute to the immune resistance to TB. This notion is
supported by our recent observation that phosphoantigen/IL2-
expanded Vc2Vd2 T effector cells can produce a homeostatic
mediator FGF-7, and coincide with attenuation against pneumon-
ic plague damages of lung tissues after pulmonary infection even
with extracellular Y. pestis [14], whose protection often requires
neutralizing Ab.
Data from the mechanistic experiments suggest that phos-
phoantigen/IL2-expanded Vc2Vd2 T effector cells producing
granulysin/perforin during Mtb infection may contribute to the in
vivo function restricting Mtb infection or dissemination while these
expanded cd T cells are actively mounting anti-TB Th1-like IFNc
cellular responses. The phosphoantigen/IL2-expanded Vc2Vd2 T
cells appear to differentiate into multi-functional effector cell
subpopulations that are able to mount anti-Mtb effector functions
via producing at least IFNc, perforin and granulysin. It is
noteworthy that Vc2Vd2 T effector cells producing granulysin/
perforin are able to limit Mtb growth in macrophages. The
capability of Vc2Vd2 T effector cells to co-produce granulysin and
perforin seems to be necessary for anti-Mtb effector function of
Vc2Vd2 T effector cells as macaque granulysin, like human
counterpart, exerts bactericidal effect on extracellular Mtb and
inhibits intracellular Mtb in presence of perforin [35]. Earlier
human studies showed that potent in vitro stimulation of human
Vc2Vd2 T cells allowed these highly-activated cd T cells to inhibit
Mtb growth and that anti-perforin/anti-granulysin antibodies
could reduce the anti-Mtb effector function [8,32,37,39]. Now, the
current study extended the previous in vitro work by demonstrating
both the in vivo co-production of granulysin/perforin by Vc2Vd2
T effector cells in lung tissues and the direct anti-Mtb activities
exerted by these two cytokine proteins. Our findings support the
notion that anti-Mtb Vc2Vd2 T effector cells and granulysin/
perforin effector cytokines might contribute to phosphoantigen/
IL2-induced resistance to Mtb infection or TB lesions, although
down-regulation of Treg for enhancing immune responses might
also play a role. Thus, phosphoantigen-differentiated Vc2Vd2 T
effector cells and in vivo co-production of granulysin/perforin in
lungs may be relevant to a mechanism underlying the in vivo
control of Mtb replication or dissemination in Picostim/IL2-
treated macaques.
Another surprising observation is that Picostim/IL2-expanded
Vc2Vd2 T cells are able to constitutively produce IL-12 without
Ag stimulation, and expansion of Vc2Vd2 T cells leads to
enhanced pulmonary immune responses of Mtb-specific ab T
effector cells. IL-12, a major cytokine critical for eliciting Th1
immune responses, is usually produced by DC or other APC, but
not T cells. Our demonstration of IL-12 production by Vc2Vd2 T
effector cells is therefore considered novel. The constitutive
production of IL-12 by Vc2Vd2 T effector cells helps to explain
indirectly how expansion/differentiation of Vc2Vd2 T effector cells
stimulation(student t test used for p values). (a). Picostim/IL-2 treated macaques exhibited greater percentage numbers of PPD-specific IFNc-
producing CD4+ T cells (top) and CD8+ T cells(bottom) in BALF than saline/BSA-treated or IL-2-treated macaques. Effector cells were measured by ICS
after PPD stimulation(n = 9/group). See Fig. S5 in Text S1 for T effector cells detected by direct ICS without antigen stimulation in vitro. (b).
Representative cytometry histograms for Vc2Vd2 T cells producing IL-12 and graph data (bottom panel) for numbers of IL-12-producing Vc2Vd2 T
cells from Picostim/IL-2, IL-2 alone or saline treatment of Mtb-infected macaques(n= 4/group). T effector cells producing IL-12 cytokine (clone C8.6,
Miltenyi) were measured by the direct ICS method in the absence of antigen stimulation, analyzed by flow cytometry (see Methods), and expressed
objectively as percents of total CD3+ T cells as cells were gated on CD3. Note that numbers in the upper left quadruple presumably denote
percentages of IL12-producing CD3+ ab+ T cells as they do not express cd TCR.
doi:10.1371/journal.ppat.1003501.g006
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by phosphoantigen/IL2 could promote pulmonary Th1-like
immune responses of CD4+ and CD8+ T cells in Mtb infection.
In fact, frequencies of pulmonary CD4+ and CD8+ Th1-like cells in
Picostim/IL2 group are significantly higher than those in saline/
BSA or IL2 alone control during primaryMtb infection. The reason
why enhanced responses were seen prominent only in pulmonary
compartment but not in blood may be due to the fact that
pulmonary Mtb infection leads to dominance of immune responses
in lung but not in peripheral blood [40]. These results suggest that
phosphoantigen expansion of Vc2Vd2 T effector cells may serve as
immune adjuvant enhancing CD4+ and CD8+ Th1 responses. The
finding also suggests that early expansion/differentiation of Vc2Vd2
T cells by phosphoantigen/IL2 during Mtb infection may not only
limit Mtb replication and dissemination, but also help promote
primary anti-TB CD4+ and CD8+Th1 responses. The surprising in
vivo observation of Vc2Vd2 T cell-driven anti-TB immunity would
open an avenue for further mechanistic studies.
To our knowledge, the current study also represents the first
appreciable attempt that amplification and differentiation of a
potentially protective Ag-specific T-cell subpopulation in Mtb
infection can confer detectable efficacy of resistance to TB in
primates. Since non-human primates resemble their human
counterparts in biology and host responses to TB, our findings
may help to rationalize future studies for evaluating cd T cell-
targeted treatment modality in chronic TB. Notably, human
Vc2Vd2 T cells can be selectively expanded in vivo by zoledronate,
a clinical drug widely used for treatment of bone-related disease, and
that zoledronate/IL-2 expansion of Vc2Vd2 T cells has been tested
as therapeutic regimen for treatment of metastatic cancers [18,19].
Thus, specific phosphoantigen/IL2 immune stimulation early
during Mtb infection rapidly expands and differentiates Vc2Vd2
T cells into multi-functional effector cells capable of mounting
anti-TB IFNc response, inhibiting Mtb growth through in vivo or
constitutive production of perforin/granulysin, and producing IL-
12 and promoting pulmonary Th1 responses of peptide-specific
CD4+ and CD8+ T cells. The observation that phosphoantigen/
IL2 expansion/differentiation of Vc2Vd2 T cells increases
resistance to TB in nonhuman primates provides a rationale to
design further studies of treatment of established TB. Such future
studies might help guide single or adjunctive phosphoantigen
expansion/differentition of Vc2Vd2 T cells for treatment of
MDR-TB or AIDS-related TB in humans.
Materials and Methods
Ethics statement
The use of macaques and experimental procedures were
approved by Institutional Animal Care and Use Committee and
Biosafety Committee (Protocols A 05-072 and A 08-029),
University of Illinois College of Medicine at Chicago (UIC), and
we followed the national and international guidelines [Interna-
tional Primatological Society (IPS) International Guidelines for the
acquisition, care and breeding of nonhuman primates] regarding
‘‘The use of non-human primates in research’’ to minimize
potential suffering of the studied macaques. Daily or weekly
clinical follow-up were taken to ensure that animals were not
suffering from severe coughing, respiratory distress, depression,
refusing to take food, body-weight loss or other potential life-
threatening signs. Humane euthanization procedures were imme-
diately taken if those signs occurred progressively.
Animals
Twenty-seven cynomolgus macaques (M. fascicularis), 4–8 year
old and 3–5 kg, were used in this study. All animals were
maintained and used in accordance with guidelines of the
institutional animal care and use committee(IACUC). Animals
were anesthetized with 10 mg/kg ketamine HCl (Fort Dodge
Animal Health, Fort Dodge, IA) i.m. for infection, bronchoalve-
olar lavage(BAL), blood samplings and treatments. All experi-
mental protocols were approved by IACUC and IBC in University
of Illinois Chicago.
Mtb infection. 500 CFU Mtb Erdman were spread into
bronchoaleveolar interface of the right caudal lung lobe using
bronchoscope-guided challenge technique as we previously
described [21,27,29]. This dose and approach consistently induced
severe TB in a total of 21 naive macaques including 9 in this study
that we had tested [27,29,41,42,43].
Picostim and IL-2 administration, and controls
Picostim and HMBPP phosphoantigen chemicals are very
similar in bioactivity and structure as they differ in only one atom
linking the carbon chain and the phosphate moiety [15]. Both
Picostim and HMBPP are specifically recognized by TCR
expressed on primate Vc2Vd2 T cells [13] not by other cd T
cell subsets or ab T cells. Picostim (.98 pure) was synthesized and
provided by the company Innate Pharma(France). In the
Picostim/IL2 co-treated group(n = 9), Picostim (25 mg/kg) was
administered i.m., as we previously reported [15], on day 23 and
day 15, respectively, after Mtb infection; recombinant human IL-2
(rhIL-2; Proleukin, Chiron, Emeryville, CA) was given i.m. at a
dose of 1.2 million IU IL-2 once daily for 5 consecutive days
beginning on the day of Picostim treatment. As a control
group(n = 9), 1.2 million IU IL-2/day was given once daily i.m.
for 5 consecutive days. As another control(n = 9), five animals
received saline and four received bovine serum albumin (BSA,
27.2 ug) in 0.5-ml s.c. for 5 consecutive days. All treated macaques
did not exhibit any notable side effects during treatments.
Bronchoalveolar lavage (BAL). This was done as we
previously described [9,21,27,29]. Briefly, prior to BAL, animals
were subjected to overnight fasting, and were tranquilized i.m.
with 1–2 mg/kg xylazine (Ben Venue Laboratories, Bedford, OH)
and 10 mg/kg ketamine HCl. For BAL, animals also received
0.05 mg/kg atropine (Phoenix Scientific, Inc., St. Joseph, MO)
i.m. as an anticholinergic and were restrained in an upright
position. A pediatric feeding tube was inserted down into the
trachea through direct visualization with a laryngoscope and
further into the right or left bronchus at the level of the carina.
10 ml of saline were instilled into the bronchus and immediately
withdrawn and repeated a maximum of 3 times until a total of 12–
15 ml BAL fluid was retrieved. This procedure generally gave rise
to fluid compositions and volumes that were comparable to the
bronchoscope-guided BAL (data not shown).
Isolation of single cell suspensions and lymphocytes from
blood and BAL fluid. These methods were described in details
in our recent publications [21,27,29].
Antigens (Ag) and Antibodies (Ab). The phosphoantigen
compound, nonpeptidic phosphorylated metabolite of isoprenoid
biosynthesis, [e.g. (E)-4-hydroxy-3-methyl-but-2-enyl pyrophos-
phate (HMBPP)] specifically recognized by primate Vc2Vd2 T
cells not by others, was produced, characterized, validated and
provided by Dr. Hassan Jomaa in Giessen, Germany. The purity
of HMBPP was .98% [16]. The phosphoantigen compound
Picostim shares with HMBPP the capacity to specifically activate
and expand Vc2Vd2 T cells[see above and [15]]. PPD were
purchased from Mycos Research (Loveland, CO). Anti-CD28
(CD28.2, BD) and anti CD49d (9F10, BD) were used in the assays
as co-stimulatory Abs. The following mAbs were used for surface
and intracellular cytokine staining for flow cytometry analyses:
Role of Vc2Vd2 T Cells in Immunity to Tuberculosis
PLOS Pathogens | www.plospathogens.org 11 August 2013 | Volume 9 | Issue 8 | e1003501
anti-human CD3 (SP34-2, BD), anti-human CD4 (OKT4,
eBioscience), anti-human CD8 (DK25, Dako), anti-human Vc2
(7A5, Thermo), anti-human Vd2(15D, Pierce, IL), anti-human
Vd1(TS8, Pierce), anti-human Vd3(P11.B, Pierce), anti-human
IFNc-Allophycocyanin (4S.B3, BD), Perforin-biotin (Pf-344,
Mabtech, Cincinnati, OH), anti-human granulysin-PE (clone
DH2, Novus Biologicals), Anti-human IL-12-PE (clone C8.6,
Miltenyi), Isotype control Abs: purified mouse IgG isotype or
mouse IgG-PE (eBioscience).
Immunofluorescent staining and flow cytometric
analysis. These were described in details in our recent
publications [15,17,27]. Briefly, PBMC and BAL cells were
stained with up to 5 Abs (conjugated to FITC, PE, allophycocya-
nin, pacific blue, and PE-Cy5 or allophycocyanin-Cy7) for at least
15 min(Staining panels: CD3/CD4/CD8/Vc2/Vd2;CD3/pan-
cd/Vd1 or Vd3) After staining, cells were fixed with 2%
formaldehyde-PBS (Protocol Formalin, Kalamazoo, MI) prior to
analysis on a CyAn ADP flow cytometer (DakoCytomation,
Carpinteria, CA). Lymphocytes were gated based on forward- and
side-scatters, and pulse-width and at least 40,000 gated events
were analyzed using Summit Data Acquisition and Analysis
Software (DakoCytomation). Absolute cell numbers were calcu-
lated based on flow cytometry data and complete blood counts
performed on a hematology system (Advia 120, Siemens, Tarry-
town, NY).
Intracellular cytokine staining (ICS) for detection of T
effector cells. ICS was done as previously described [21,27,29].
105–106 BAL cells or 106 PBMC plus mAbs CD28 (1 mg/ml) and
CD49d (1 mg/ml) were incubated with PPD (25 ug/ml, from
Mycos Research (Loveland, CO), HMBPP(80 ng/ml) or media
alone in 100 ml final volume for 1 h at 37uC, 5% CO2 followed by
an additional 5 h incubation in the presence of brefeldin A
(GolgiPlug, BD). After staining cell-surface CD3, CD4, CD8 or Vc2
for 30 min, cells were permeabilized for 45 min (Cytofix/cytoperm,
BD) and stained for another 45 min to detect IFNc, perforin or IL-
12 before re-suspending in 2% formaldehyde-PBS. ICS panels:
CD3-PEcy7/CD4-APC/Vc2-FITC/IFNc-PE/perforin-PB;CD3-
PEcy7/CD8-APC/Vc2-FITC/IFNc-PE/perforin-PB;CD3-PEcy7/
CD4-APC/Vc2-FITC/IL12-PE; CD3-PEcy7/CD4-APC/Vc2-
FITC/mouse IgG-PE. No positive staining of PBMC or BAL
samples collected overtime after infection/treatments was seen in
ICS when using the mouse IgG isotype control(data not shown).
Direct ICS for measuring T effector cells constitutive pro-
ducing cytokineswithout in vitro antigen stimulation. Direct
ICS was adapted from the conventional ICS protocol, and the major
modification was that PBMCor BAL cells were directly measured by
ICS for intracellular cytokines without prior in vitro Ag stimulation as
we recently described [17,27,28,29,44]. Direct ICS approach was
characterized and validated extensively in vitro and in vivo conditions
as we previously reported [17,22,27,28,29,30]. Briefly, PE-mouse
IgG served as internal isotype control and did not yield any positive
ICS staining over time after treatments (data not shown). As in vivo
controls, longitudinal direct ICS analyses of PBMC or BAL cells
obtained biweekly for 6 weeks from 3 normal uninfected macaques
or during acute- and chronic-SHIV-infection of four macaques did
not detect measurable increases in IFNc- or perforin-producing Vc2
or CD4+ T cells in PBMC [17,28]. In addition, direct ICS did not
detect increased levels of IL-17- or IL-22-producing T-cells in blood
over time during acute- and chronic-SHIV-infection [17,27].
In situ confocal microscopic analysis of Vc2 TCR,
perforin and granulysin in lung tissue sections of Mtb-
infected macaques. The OCT lung tissue blocks were cut into
6 um sections using a cryostat as we previously described
[14,29,42]. The frozen tissue sections were fixed with acetone
for 10 min, rinsed with PBS and then blocked with Protein
Blocking Serum-Free buffer (Dako, X0909) for 20 min. Sections
were incubated for 1 hr in dark with FITC-conjugated anti-
human TCR Vc2 mAb (clone 7A5, Thermo), 1:10 diluted
biotinylated anti-human perforin mAb (clone pf-344, MABTECH
AB) and PE-conjugated anti-human granulysin mAb (clone DH2,
Novus Biologicals). The sections were rinsed with PBS, and then
incubated for 30 min in dark with APC-conjugated streptavidin
(Cat# 405207, Biolegend). The sections were then rinsed with
0.02% Tween20-PBS, and cover-slipped and mounted on slides
using fluorescence mounting medium with 49, 6-diamidino-2-
phenylindole (DAPI) (H-1200, Vector). The edges of cover slip
were sealed with nail polish. The slides were imaged by a Carl
Zeiss (Thornwood, NY) LSM510 Meta5 laser scanning confocal
microscope equipped with a 636/1.2 water-immersion objective.
FITC-conjugated mouse IgG served as isotype control staining,
and did not give rise to fluorescent images on the sections under
the confocal(data not shown).
Bacterial colony forming units (CFU) counts in lung lobe
tissue homogenates. To objectively measure CFU counts in
lung lobes, we used the sampling strategy and CFU determination
as previously described [21,22,27,29,45]. Briefly, approximately a
half of cut-sections of the right caudal lobe (the infection site), the
right middle lobe or the left caudal lobe from each animal were
taken for CFU determination after the extensive gross pathologic
evaluation was accomplished. If there were gross TB lesions in the
respective lobe, a half of the lung tissue containing approximately
50% lesions was taken. If no visible lesions were seen in the
respective lobe, a random half of tissue was taken for evaluation.
Tissue homogenates were made using a homogenizer (PRO 200,
PRO Scientific INC, CT) and diluting the homogenate in sterile
PBS+0.05% Tween-80. 5-fold serial dilutions of samples were
plated on Middlebrook 7H11 plate(BD).
Gross pathologic analysis and the scoring system
measuring TB lesions. Details were described in our previous
publications [21,22]. Briefly, animals were euthanized by intrave-
nous barbiturate overdose, and immediately necropsied in a
biological safety cabinet within a BSL-3 facility. Standard gross
pathologic evaluation procedures were followed by the blinded
pathologist and associates, with each step recorded and photo-
graphed at day 65 after Mtb infection. Lung lobes, bronchial,
mesenteric, axillary and inguinal lymph nodes, tonsils, and other
major organs were collected and labeled. Multiple specimens from
all tissues with gross lesions and remaining major organs were
harvested. Gross observations including but not limited to the
presence, location, size, number and distribution of lesions were
recorded. The scoring system [20,21,22] was excised to calculate
gross pathology scores for TB lesions in lungs infected by
bronchoscope-guided inoculation. For each of lung lobes, granu-
loma prevalence was scored 0–4 for (i) no visible granulomas, (ii)
1–3 visible granulomas, (iii) 4–10 visible granulomas, (iv) .10
visible granulomas, and (v) miliary pattern of granulomas,
respectively. Granuloma size was scored 0–3 for (i) none present,
(ii) ,1–2 mm, (iii) 3–4 mm, and (iv) .4 mm, respectively.
Pulmonary consolidation or atelectasis as viewed from organ
exterior and cut surfaces were scored 0–2 for (i) absent, (ii) present
focally in one lobe, and (iii) focally extensive within a lobe or
involving multiple lobes. One score was also given for the presence
of tuberculosis-related focal parietal pleural adhesions, pleural
thickening and opacification, or pulmonary parenchymal cavita-
tion. For hilar lymph nodes, enlargements were scored 0–3 for (i)
visible but not enlarged, (ii) visibly enlarged unilaterally (#2 cm),
(iii) visibly enlarged bilaterally (#2 cm), (iv) visibly enlarged
unilaterally or bilaterally .2 cm, respectively. Tuberculosis lesions
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in hilar lymph nodes were scored 0–4 for (i) no granulomas visible
on capsular or cut surface, (ii) focal or multifocal, circumscribed,
non-coalescing granulomas, ,2 mm, (iii) coalescing solid or
caseating granulomas occupying,50% of nodal architecture, (iv)
coalescing solid or caseating granulomas occupying .50% of
nodal architecture, with residual nodal components still recogniz-
able, and (v) complete granulomatous nodal effacement and
caseation, respectively. One score was also given for tuberculosis-
associated changes in other thoracic nodes. The tuberculosis
lesions in each of extrathoracic organs were scored similarly as
each lung lobe. The pathology scoring of infected tissues was
conducted in a blinded fashion.
Microscopic analysis of TB lesions. This was done as we
previously described [21,41,44]. Briefly, the extent of involvement
for each lung lobe was determined using digital scans to record
total pixel counts on H&E stained material and specimen area
measured in square cm using Image-Pro Plus software (Media-
Cybernetics, Silver Spring, MD), as previously described
[21,22,41,45]. Granulomas were objectively compared for size,
type, distribution pattern and cellular composition (absence or
presence with degrees of lymphocytic cuff, mineralization, fibrosis,
multinucleated giant cells, and epithelioid macrophages) between
and within monkey groups.
Vc2Vd2 T effector cell-based inhibition of intracellular
Mtb growth. This was done through co-culturing Mtb-infected
autologous monocytes/macrophages and Vc2Vd2 T effector cell
lines as we reported [29]. Phosphoantigen-activated Vc2Vd2 T
effector cell lines were generated from three Mtb-exposed
macaques using the approach as previously described [21]. Briefly,
Vd2 T cells were purified by immunomagnetic beads [15], and
then activated and expanded through co-culturing with BCG-
infected autologous monocyte-derived DC [29] in the conditioned
growth medium as previously described [31]. Up to 90% of these
Vd2+ T cells co-expressed Vc2(data not shown) after the 14-day
co-culture with BCG-infected DC in the conditioned medium
[31]. To generate Mtb-infected monocytes/macrophages, PBMC
were cultured on plastic tissue culture dishes for 4 days at 37uC,
5% CO2, thereafter non-adherent cells were discarded, and
adherent cells were collected by scraping with a cell scraper. The
cell suspension contained 80–90% macrophages. Adherent
monolayers (56104/well in 96-well plate) were infected with
Mtb at an MOI of 10:1. After 3 h of incubation at 37uC,
supernatants were aspirated and wells were washed three times to
remove non-ingested mycobacteria. Mtb-infected monocytes were
then co-cultured at a ratio of 1:10 with Vc2Vd2 T effector cell
lines (56105/well) in multiple wells of a 96-well plate. Bead-
enriched autologous CD20+ B cells served as a control. After co-
culturing for 72 hrs, cells were lysed in lysis buffer (0.067% SDS in
Middlebrook 7H9), and lysates were plated in 10-fold serial
dilutions on Middlebrook 7H11 agar(BD) and incubated for 3
weeks in 5% CO2 at 37uC.
Production of soluble macaque granulysin and perforin
proteins. Macaque full-length granulysin and perforin cDNA
clones [41] were used to subclone DNA constructs that encode the
active granulysin bearing C-terminal portion 83 amino acid (aa)
residues and the active perforin comprised of C-terminal portion
125 aa, respectively, using the PCR-based cloning approach [34].
The purified PCR products were digested, ligated to the vector
pET-30 (Novagen) and transformed into E. coli competent cells
BL21 (DE3, Novagen). Selected cells with correct constructs were
cultured in LB- kanamycin (30 mg/ml) medium overnight, and
once the cultured medium reached about 0.6 at OD600, 1 mmol/
L of isopropyl thio-b-D-galactoside (IPTG) was added to induce
protein expression via vigorous shaking. The expression cells were
pelleted and lysed to collect the cytoplasm and inclusion bodies,
and characterized for expression and location of these proteins by
SDS-PAGE and Western blot assays. To purify recombinant
proteins, the cell pellets were harvested from large-scale expression
(induced for 5,12 hours at 28uC) by centrifugation, resuspended
for 30 minutes in 20 mM/L of Tris-HCl (pH 7.6) buffer
containing 20 mg/ml of lysozyme, and then lysed by sonication
(Microson) for 5610 seconds in ice-bath. The lysates were
centrifuged at 10,0006g for 30 minutes at 4uC to remove the
supernatants, and the collected inclusion bodies containing
recombinant proteins were solubilized with Guanidinium Buffer
(Guanidine HCl 6M/L, NaCl 500 mM/L, sodium phosphate
20 mM/L, PMSF 0.1 mM/L). Soluble samples were bound to Ni-
NTA agarose (Qiagen) to purify 66His tagged granulysin or
perforin by affinity chromatography under denaturing conditions.
Redox environment, buffer composition, protein concentration
and temperature of refolding procedures were examined to
optimize the refolding conditions for the recombinant proteins
using Pro-Matrix protein refolding kit (Pierce). A presence of
detection tags (S- and His-tag) in the target protein was monitored
for the success of refolding by SDS-PAGE and Western blot.
Refolded samples were then passed through a S-protein agarose
(Novagen) column to purify S-tagged proteins. After dialysis with
PBS and concentration by 10,20 K cut-off iCON concentrator
(Pierce), recombinant Enterokinase (rEK, Novagen) was used to
cleave the specific cleavage site of AspAspAspAspLys between S-
tag sequence and expressed target protein. After removing the free
rEK and the N-terminal S-tag portion by Enterokinase Cleavage
Capture Kit (Novagen), purified recombinant protein was
evaluated for its molecular mass weight by SDS-PAGE analysis
and measured for concentration using BCA protein assay kit
(Pierce). Specific anti-human granulysin C domain [37] and
perforin C-terminus antibodies [46,47] were used in Western blot
assays, as previously described [13,34], to confirm purified
granulysin and perforin.
Macaque granulysin-mediated killing of extracellular
Mtb. 56103 CFU of Mtb H37Rv suspension were distributed
in each well of a 96-well plate in presence of 50 mM, 10 mM,
1.0 mM, or 0.1 mM (triplicate for each) purified granulysin or
perforin protein at a final volume of 50 ml 7H9 medium, and then
incubated in 5% CO2 at 37uC for 72 hours. As negative controls,
medium only and four different concentrations of recombinant
heat shock protein (HSP70, expressed in E. coli, Sigma) were
similarly added to individual wells with defined CFU of Mtb. The
samples were then processed in ten-fold serial dilutions with
Middlebrook 7H9 broth, and each dilution was plated for CFU on
Middlebrook 7H11 agar(BD) and incubated in 5% CO2 at 37uC
3–4 weeks. The killing percentage of extracellular Mtb bacteria
was calculated as [CFUs in medium-only control - CFUs in
granulysin or perforin or HSP70]/CFUs in medium-only control
[37].
Macaque granulysin/perforin-mediated inhibition of
intracellular Mtb. Monocytes as prepared above were infected
with Mtb H37Rv using the similar procedure as described above.
Mtb-infected monocytes were distributed in a 96-well plate at a
density of 1.06104 per well in presence of 0.1 mM, 1.0 mM, 10 mM
and 50 mM(duplicate for each concentration) of recombinant
granulysin or perforin or both. The co-cultures were incubated in
5% CO2 at 37uC in a final volume of 100 ml per well with RPIM-
1640 medium. HSP 70 and medium-only treatments were
included as negative controls, respectively. After 72 hours culture,
the cells were lysed, and the lysates were measured for CFU in 10-
fold serial dilutions as described above. The inhibiting percentage
of intracellular Mtb bacteria was calculated as [CFUs in
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monocytes treated with medium-only control - CFUs in mono-
cytes treated with granulysin, perforin or HSP70]/CFUs in
monocytes treated with medium-only control [37].
Statistical analysis. The multivariate analysis of variance
(ANOVA) and student t test were used, as previously described
[14,21], to statistically analyze the data for differences between
picostim/IL2-treated and control groups. Wherever non-gaussian
distribution of data is occurring/expected, e.g. with scoring of
pathology, non-parametric analysis was utilized. When non
parametric statistical analysis of CFU and pathology scores was
performed, similar results were seen as the above parametric
method(data not shown). Since limited numbers of macaques/
group were employed in this proof-of-concept study, medians, not
means, of CFU and gross pathology scores were shown in the
respective figures and used for statistical analyses(significance is
similar as the means).
Supporting Information
Text S1 Fig. S1. Picostim/IL2 treatment, while expanding
Vc2Vd2 T cells, could confer immune resistance to TB lesions in
lungs after pulmonary Mtb infection. Shown are dditional digital
photos of cut sections of lung lobes from other macaques(a total of
27). Please see Fig. 2 legend in Text for detailed description of
photos. Fig. S2. Shown are additional histopathology photos for
other macaques from Picostim/IL-2-treated and control groups.
Please see Fig. 3b legend in Text for detailed description of photos.
Original magnification 6100 for all photos. Fig. S3a. Phos-
phoantigen-expanded Vc2Vd2 T cells in pulmonary compart-
ments possess the capacity to de novo produce anti-Mtb cytokines
IFNc, perforin and granulysin without phosphoantigen HMBPP
stimulation in vitro. Shown are representative flow cytometry
histograms (left) of IFNc-producing(top panels) and perforin-
producing(lower panels) Vc2Vd2 T effector cells gated on CD3
and graph data (right) of numbers of Vc2Vd2 T effector cells in
BALF collected overtime from Picostim/IL-2-treated and control
groups. Effector cells were measured by ICS without HMBPP
stimulation. See Fig. 4a legend in Text for detailed description.
Fig. S3b. Additional representative in situ confocal microscopic
images (636NA) of Vc2Vd2 T effector cells producing perforin
and granulysin in lung tissue sections from other macaques. See
Fig. 4b legend in Text for detailed description. Fig. S3c.
Immunohistochemistry analysis of Vc2 T cells in lung parenchy-
ma and granuloma tissues. Note that more Vc2 T cells were
detected in ‘‘tiny’’, small and large granulomas tissues in Picostim/
IL2-treated macaques than those in control IL2 alone- and saline/
BSA-treated macaques. Magnifications were indicated. Immuno-
histochemistry analysis of Vc2 T cells was essentially the same as
previously described. Fig. S3d. Vc2Vd2 T effector cells that
expanded and differentiated in vivo at day 14 after Picostim/IL-2
treatment could recognize Mtb-infected autologous macrophages,
leading to inhibition of intracellular Mtb growth, and such
inhibition could be reduced by antibodies against granulysin/
perforin. Macaque PBMC frozen down at day 14 after Picostim/
IL-2 treatment were cultured for 7 days in presence of HMBPP/
IL2, and used to purify Vc2Vd2 T cells as described in Methods.
Vc2Vd2 T cells were incubated for 4 days with autologous Mtb-
infected monocytes(prepared using day 56 PBMC) at E:T ratio of
10 in the presence of anti-perforin/granulysin Abs(see clones ID in
Methods, 10 mg/ml for each) or IgG isotype control (10 ug/ml) as
described in Methods. The cultured cells were lysed, and CFU
counts in lysate were determined as described in Methods. N= 3.
Fig. S4. Shown are SDS-PAGE and Western blot data for analysis
of recombinant macaque perforin and granulaysin proteins purified
from E-coli expression system [29]. See Fig. 5 legend in Text for
details. Fig. S5. Picostim/IL-2 treated macaques exhibited greater
numbers of IFNc-producing CD4+ T cells (top) and CD8+ T
cells(bottom) in BALF than saline/BSA-treated or IL-2-treated
macaques. Effector cells were measured by direct ICS without
antigen stimulation in vitro. See Fig. 6 legend in Text for details.
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